Ophthalmic Drugs: World Market Prospects 2013-2023

Date: March 27, 2013
Pages: 222
Price:
US$ 2,635.00
License [?]:
Publisher: Visiongain
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O13ECFEB8C0EN
Leaflet:

Download PDF Leaflet

Ophthalmic Drugs: World Market Prospects 2013-2023
Report Details

How to find trends and revenue predictions for the ophthalmic drug industry

What are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for ocular drugs.

Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses.

Therapies for treating eye disorders and diseases have rising demand. See the future of ophthalmic medicines and discover how sales of ocular drugs can increase.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), business outlooks and research and development (R&D). You receive 48 tables, 74 charts and 9 interviews.

Is finding commercial details a challenge? With our report you can get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening.

Discover areas that will prosper, reducing the risk of your being left behind.

The following sections show how you benefit from our new study.

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:
  • Glaucoma treatments
  • Anti-allergy, anti-inflammatory and anti-infective agents
  • Retinal disorder treatments
  • Dry eye treatments
  • Other medicines.
With our investigation you gain business research and analysis with individual sales predictions and discussions. You find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can gain competitive advantages by understanding the trends, opportunities and challenges facing the ophthalmic drug market.

See revenue forecasts for products

How will leading ophthalmic drugs perform to 2023 at world level? Our work shows you revenue forecasts for 20 top products, including Lucentis, Eylea, Visudyne, Xalatan/Xalacom, Patanol and Restasis.

Discover how high revenues can go, to 2023, finding areas and years with highest predicted growth. You see what's happening, understanding trends, challenges and opportunities.

Our work also breaks the main world forecast into leading geographical markets.

What prospects for leading countries?

Developments worldwide will influence the market, especially rising demand in emerging countries. Our report shows outlooks for the industry.

You see individual forecasts to 2023 for ten national markets, getting overall revenues:
  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5)
  • Brazil, India and China
Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance.

You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.

Research and development - assess innovation, trends and possibilities

What about R&D - the pipeline for new drugs? You see trends for these areas:
  • Glaucoma treatments
  • Anti-allergy, anti-inflammatory and anti-infective agents
  • Retinal disorder treatments
  • Dry eye treatments
  • Other progress in ophthalmic treatments.
Our study also discusses these candidates and others:
  • Neuroprotective agents
  • RNA interference technology
  • Ocular implants
  • Gene therapy.
There's strong, promising R&D for treating ocular disorders. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. See what's happening.

What affects ophthalmic drugs treatments from 2013?

Our report discusses issues and events affecting that industry and market from 2013 onwards:
  • Increasing prevalence of eye disorders
  • Reimbursement for ophthalmic pharmaceuticals
  • Patient compliance
  • Generic competition.
Also, we discuss these aspects of the field:
  • Development of new drug delivery methods and formulations
  • Sustained-release ocular Implants
  • New ophthalmic therapeutic applications for drugs.
See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market value

We predict the overall world market for ophthalmic drugs will reach $21.9bn in 2015, and expand further to 2023.

What are leading companies doing? Our work discusses Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies, evaluating prospects of the industry and market.

Prospects for R&D are strong, and from 2013 onwards there will arise many opportunities. Our work shows you the technological and commercial possibilities, helping you stay ahead.

Eight ways Ophthalmic Drugs: World Market Prospects 2013-2023 helps

To sum up, our investigation gives you the following knowledge:
  • Revenues to 2023 for the overall world market and 5 submarkets - you discover that industry's prospects
  • Forecasting to 2023 for the US, Japan, Germany, France, UK, Spain, Italy, Brazil, India and China - you see leading national sales potentials
  • Discover revenue forecasts to 2023 for 20 leading products -- you find sales outlooks for top brands
  • Review R&D, seeing pipeline trends by therapeutic area - you hear about progress in those research areas, finding technological and medical possibilities
  • Opinions on the sector - you read our industry interviews
  • Understanding of competition and opportunities - you see what affects that industry, learning what shapes its future
  • Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths
  • Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.
You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for insight.

You see prospects for ophthalmic drugs by ordering now

Visiongain's new study is for everyone needing analysis of the industry and market for ophthalmic medicines. You find data, trends and predictions. Please order our report now.
1. EXECUTIVE SUMMARY

1.1 Aims, Scope and Format of the Report
  1.1.1 Chapter Outlines
1.2 Research and Analysis Methods

2. OPHTHALMIC DISORDERS AND TREATMENTS

2.1 The Ophthalmic Drug Market
2.2 Ophthalmic Disorders
2.3 The Human Eye and the Vision Process
2.4 Glaucoma
  2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma
  2.4.2 Closed Angle Glaucoma
  2.4.3 Secondary Glaucoma
  2.4.4 Congenital Glaucoma
  2.4.5 Normal Tension Glaucoma
  2.4.6 Ocular Hypertension
  2.4.7 Glaucoma Risk Factors
  2.4.8 Diagnosis of Glaucoma
  2.4.9 Prevalence of Glaucoma
  2.4.10 Treatment of Glaucoma
  2.4.11 Prostaglandins are the First-Line Treatment of Choice
  2.4.12 Second-Line Glaucoma Treatments
  2.4.13 Combination Treatments
  2.4.14 Laser Treatment
  2.4.15 Surgery (Trabeculectomy)
2.5 Age-Related Macular Degeneration (AMD)
  2.5.1 Dry AMD
  2.5.2 Wet AMD
  2.5.3 AMD Risk Factors
  2.5.4 Diagnosis of AMD
  2.5.5 Prevalence of AMD
  2.5.6 Treatment of AMD
2.6 Diabetic Retinopathy
  2.6.1 Diagnosis of Diabetic Retinopathy
  2.6.2 Prevalence of Diabetic Retinopathy
  2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
  2.6.4 Pharmaceutical Treatments
2.7 Ophthalmic Allergies
  2.7.1 Allergic Conjunctivitis is the Most-Common Eye Allergy
  2.7.2 Ophthalmic Allergy Treatments
2.8 Ophthalmic Inflammatory Disorders
  2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease
  2.8.2 Ophthalmic Inflammatory Drugs
2.9 Ophthalmic Infections
  2.9.1 Types of Eye Infection
  2.9.2 Treatment of Eye Infections
2.10 Dry Eye Syndrome
  2.10.1 Causes and Prevalence of Dry Eye Syndrome
  2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears
  2.10.3 Prescription-Only Drugs for Dry Eye are Limited
  2.10.4 Tear Augmenters (Punctal Plugs)

3. THE WORLD OPHTHALMIC PHARMACEUTICAL MARKET, 2013-2023

3.1 The Ophthalmic Pharmaceutical Market in 2011
  3.1.1 The Anti-Glaucoma Segment had the Largest Market Share in 2011
  3.1.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2011
  3.1.3 Four Manufacturers Account for Over Half the Market
3.2 World Ophthalmic Pharmaceutical Market Forecasts, 2013-2023
  3.2.1 Growth Expected in the Ophthalmic Pharmaceutical Market from 2013-2017
  3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market from 2018-2023?
3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2013-2023
  3.3.1 Retinal Disorders Will Power Growth from 2011-2017
  3.3.2 Retinal Disorder Revenue Growth Will Slow from 2018-2021
  3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma Drugs from 2021 to 2023

4. THE ANTI-GLAUCOMA MARKET, 2013-2023

4.1 The Anti-Glaucoma Drug Market in 2011
  4.1.1 Prostaglandin Analogues Led the Anti-Glaucoma Market in 2011
  4.1.2 Xalabrands (Xalatan/Xalacom)
  4.1.3 Lumigan Franchise
  4.1.4 Cosopt/Trusopt
  4.1.5 Travatan Z
  4.1.6 Alphagan
  4.1.7 Combigan
  4.1.8 Azopt
  4.1.9 Extravan/Duotrav
4.2 Anti-Glaucoma Market Forecasts, 2013-2023
  4.2.1 Generic Competition Will Affect the Anti-Glaucoma Market from 2011-2017
  4.2.2 Novel Anti-Glaucoma Drugs Will Drive Growth from 2018-2023
  4.2.3 Xalabrands (Xalatan/Xalacom) Sales Forecast, 2013-2023
  4.2.4 Lumigan Franchise Sales Forecast, 2013-2023
  4.2.5 Cosopt/Trusopt Sales Forecast, 2013-2023
  4.2.6 Travatan Z Sales Forecast, 2013-2023
  4.2.7 Alphagan Sales Forecast, 2013-2023
  4.2.8 Combigan Sales Forecast, 2013-2023
  4.2.9 Azopt Sales Forecast, 2013-2023
  4.2.10 Extravan/DuoTrav Sales Forecast, 2013-2023

5. THE OPHTHALMIC ANTI-ALLERGY/INFLAMMATORY/INFECTIVE MARKET

5.1 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market in 2011
  5.1.1 Patanol
  5.1.2 Vigamox/Vegamox
  5.1.3 TobraDex
  5.1.4 Pataday
  5.1.5 Cravit
  5.1.6 Acular
  5.1.7 Xibrom/Bromday
5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2013-2023
  5.2.1 Innovation in the Anti-Allergy/Inflammatory/Infective R&D Pipeline
  5.2.2 Patanol Sales Forecast, 2013-2023
  5.2.3 Vigamox Sales Forecast, 2013-2023
  5.2.4 TobraDex Sales Forecast, 2013-2023
  5.2.5 Pataday Sales Forecast, 2013-2023
  5.2.6 Cravit Sales Forecast, 2013-2023
  5.2.7 Acular Sales Forecast, 2013-2023
  5.2.8 Xibrom/Bromday Sales Forecast, 2013-2023

6. THE RETINAL DISORDER MARKET, 2013-2023

6.1 The Retinal Disorder Treatment Market
  6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorders Market
  6.1.2 Lucentis Controls the Retinal Disorder Market in 2011
  6.1.3 Visudyne was the Second Highest Selling Retinal Disorder Drug in 2011
  6.1.4 Eylea, the New Retinal Disorder Drug in 2011
  6.1.5 Lucentis has Sidelined Macugen but Faces Potent Threat from Avastin and Eylea
  6.1.6 Eylea Clinical Trials Data
  6.1.7 Eylea and the Davis-Smyth VEGF-Trap Patents
  6.1.8 Allergan's Ozurdex, First Drug Therapy for Macular Oedema
6.2 Retinal Disorder Market Forecasts, 2013-2023
  6.2.1 Eylea and Lucentis Will Drive the Retinal Disorder Market from 2011-2017
  6.2.2 Novel Drugs and New Disease Treatments will Drive Growth from 2018-2023
  6.2.3 Lucentis Sales Forecast, 2013-2023
  6.2.4 Eylea Sales Forecast, 2013-2023
  6.2.5 Visudyne Sales Forecast, 2013-2023

7. THE DRY EYE MARKET, 2013-2023

7.1 The Dry Eye Drug Market in 2011
  7.1.1 Restasis - Prescription Drug for Dry Eye
  7.1.2 Allergan's Refresh Brand, including Celluvisc, is the Second-Best-Selling Dry Eye Product
  7.1.3 Hyalein: Marketed in Japan and China
  7.1.4 The OTC Market for Artificial Tears is Fragmented and Competitive
7.2 Dry Eye Market Forecasts, 2013-2023
  7.2.1 Increased Sales of Dry Eye Prescription Drugs Forecasted from 2013-2017
  7.2.2 Growth in the Dry Eye Market Will Decline after 2013
  7.2.3 Restasis Sales Forecast, 2013-2023
  7.2.4 Refresh Brand including Celluvisc: Sales Forecast, 2013-2023
  7.2.5 Hyalein Sales Forecast, 2013-2023

8. ISSUES AFFECTING THE MARKET FOR OPHTHALMIC DRUGS, 2013-2023

8.1 SWOT Analysis of the Ophthalmic Drugs Market
8.2 Strengths of the Ophthalmic Pharmaceutical Market
  8.2.1 Development of New Drug Delivery Methods and Formulations
  8.2.2 Intraocular Injections
  8.2.3 Sustained-Release Ocular Implants
  8.2.4 Gene Therapy and RNA Interference Technology
  8.2.5 New Ophthalmic Therapeutic Applications for Drugs
  8.2.6 Development of Neuroprotective Anti-Glaucoma Medications
8.3 Weaknesses of the Ophthalmic Pharmaceutical Market
  8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition
  8.3.2 Avastin is Cannibalising Lucentis Revenues
8.4 Opportunities for the Ophthalmic Pharmaceutical Market
  8.4.1 Aging of the World Population
  8.4.2 Increasing Prevalence of Diabetes and Other Health Challenges
  8.4.3 Increasing Prevalence of Eye Disorders
  8.4.4 Retinal Disorders Will Have the Most-Marked Increases in Prevalence
  8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders
  8.4.6 Generous Reimbursement for Ophthalmic Pharmaceuticals
8.5 Threats Facing the Ophthalmic Pharmaceutical Market
  8.5.1 Patient Compliance
  8.5.2 The Rate of Diagnosis for Eye Disorders is Low

9. NATIONAL MARKETS FOR OPHTHALMIC PHARMACEUTICALS, 2013-2023

9.1 Ophthalmic Pharmaceuticals: Leading National Markets, 2011
9.2 Leading Developed-Country Ophthalmic Pharmaceutical Markets
  9.2.1 The US Ophthalmic Pharmaceutical Market, 2013-2023
  9.2.2 The Japanese Ophthalmic Pharmaceutical Market, 2013-2023
  9.2.3 Leading European Ophthalmic Pharmaceutical Markets, 2013-2023
9.3 Emerging-Economy Ophthalmic Pharmaceutical Markets
  9.3.1 Ophthalmic Pharmaceuticals in Developing Countries
  9.3.2 The Chinese Ophthalmic Pharmaceutical Market, 2013-2023
  9.3.3 The Indian Ophthalmic Pharmaceutical Market, 2013-2023

10. THE OPHTHALMIC PHARMACEUTICAL R&D PIPELINE

10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Agents
10.2 The Anti-Glaucoma Pipeline
  10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development
  10.2.2 Taflotan/DE-085 (Santen/Asahi)
  10.2.3 Azarga (Alcon)
  10.2.4 PF-4217329 (Pfizer)
  10.2.5 Anecortave (Alcon)
  10.2.6 DNB-001 (Danube)
  10.2.7 BVT.28949 (Biovitrum)
  10.2.8 OT-730 (Othera/QLT)
  10.2.9 AL-37807 (Alcon/Novartis)
  10.2.10 QLT's Punctal Plug Delivery Technology
  10.2.11 PF-03187207 (NicOx/Pfizer)
  10.2.12 Y-39983 (SNJ-1656/Sanju)
  10.2.13 DE-111/DE-118 (Santen)
10.3 The Ophthalmic Anti-Allergy Pipeline
  10.3.1 Bepreve (ISTA/Senju)
  10.3.2 FOV1101/Prednisporin (Fovea/CombinatoRx)
  10.3.3 DE-103 (Santen)
  10.3.4 DE-114 (Santen)
  10.3.5 Vekacia (Ciclosporin/Santen)
10.4 The Ophthalmic Anti-Inflammatory Pipeline
  10.4.1 T-Pred (ISTA)
  10.4.2 AzaSite Plus/ASV-502 (InSite Vision)
  10.4.3 AzaSite Xtra/ISV-405 (InSite Vision)
  10.4.4 Durezol (Senju/Sirion Therapeutics/Alcon)
  10.4.5 Luveniq (Lux Biosciences)
  10.4.6 Simulect (Cerimon)
  10.4.7 EGP-437 (EyeGate Pharma)
10.5 The Ophthalmic Anti-Infective Pipeline
  10.5.1 TobraDex ST (Alcon/Novartis)
  10.5.2 ISV-403/Besifloxacin (Bausch & Lomb)
  10.5.3 Moxifloxacin/Dexamethasone (Alcon/Novartis)
  10.5.4 Aganocide (Alcon/NovaBay)
  10.5.5 Finafloxacin (Alcon/MerLion)
10.6 The Retinal Disease Pipeline
  10.6.1 Retinal Diseases Have the Richest Pipeline
  10.6.2 Jetrea (ThromboGenics/Novartis)
  10.6.3 Arxxant (Eli Lilly/Alcon/Takeda)
  10.6.4 Recombinant Human VEGF Receptor-Fc Fusion Protein (Chengdu Kanghong Biotech)
  10.6.5 Ozurdex (Allergan)
  10.6.6 MC-1101 (MacuCLEAR)
  10.6.7 Vitrase/Vitragen (ISTA)
  10.6.8 DE-109 (Santen)
  10.6.9 Bevasiranib/Cand5 (OPKO Health)
  10.6.10 Atacand/TCV-116 (AstraZeneca/Takeda)
  10.6.11 Medidur Technology and Iluvien (pSivida/Alimera Sciences/Pfizer)
  10.6.12 NT-501 (Neurotech)
  10.6.13 Microplasmin (ThromboGenics)
  10.6.14 Novadur/Sustained-Release Brimonidine (Allergan)
  10.6.15 RTP801i-14/PF-4523655/PF-655 (Quark/Silence/Pfizer)
  10.6.16 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
  10.6.17 DARPin/MP0112/AGN-150998 (Allergan)
  10.6.18 ATG-3 (CoMentis)
  10.6.19 OT-551 (Othera)
  10.6.20 Fovista (Ophthotech)
  10.6.21 Fenretinide (Sirion Therapeutics/ReVision)
  10.6.22 Pazopanib (GlaxoSmithKline)
  10.6.23 RPE65 Gene Therapy (Targeted Genetics)
  10.6.24 Zybrestat (OXiGENE/Symphony ViDA)
  10.6.25 Lucentis (Novartis) for Pathological Myopia
  10.6.26 AtuRNAi/PF-04523655 (Pfizer)
  10.6.27 RN6G/PF-04382923 (Pfizer)
  10.6.28 iSONEP
  10.6.29 Squalamine (OHR Pharmaceutical)
  10.6.30 ESBA 1008 (Alcon)
  10.6.31 Pan-90806 (PanOptica)
  10.6.32 PDS 1.0 (ForSight VISION4)
  10.6.33 AVA-101(Avalanche Biotechnologies)
  10.6.34 AAV2-sFLT01 (Genzyme)
  10.6.35 RetinoStat (Oxford BioMedica)
  10.6.36 IBI-20089 (Icon Bioscience)
  10.6.37 Volociximab (Ophthotech)
  10.6.38 JSM6427 (Shire)
  10.6.39 AL-39324 (Alcon)
  10.6.40 Vatalanib (Novartis)
  10.6.41 TG100801 (Sanofi)
  10.6.42 AL-78898A (Alcon)
  10.6.43 Soliris (Alexion)
  10.6.44 FCFD4514S (Genentech)
  10.6.45 ARC1905 (Ophthotech)
  10.6.46 AGN208397 (Allergan)
  10.6.47 ACU-4429 (Acucela)
  10.6.48 Tandospirone (Alcon)
  10.6.49 VAR10200 (Varinel)
  10.6.50 Betamethasone Microsphere (Santen)
  10.6.51 SK-0503 (Sanwa Kagaku Kenkyusho)
  10.6.52 Cortiject (Novagali Pharma)
  10.6.53 ALG-1001 (Allegro Ophthalmics)
  10.6.54 Difluprednate (SJE-2079/Sanju)
10.7 The Dry Eye Pipeline
  10.7.1 Prolacria (Inspire/Allergan/Santen)
  10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics)
  10.7.3 Rebamipide (Otsuka/Acucela)
  10.7.4 DE-101/Rivoglitazone (Santen)
  10.7.5 Ecabet Sodium (ISTA)
  10.7.6 Remura (ISTA)
  10.7.7 SAR 1118 (SARcode)
  10.7.8 DE-110 (Santen)
  10.7.9 DE-089 (Santen)
  10.7.10 Cyclokat (Ciclosporin/Santen)
  10.7.11 Tofacitinib (Pfizer)
10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth Stimulators

11. EXPERT VIEWS FROM OUR SURVEY

11.1 Professor Leonard Bielory, MD, Director, STARx Allergy and Asthma Centre, LLC, and Professor of Medicine, Paediatrics, Ophthalmology and Visual Sciences, and Centre for Environmental Prediction, Rutgers University, Springfield, NJ, USA
  11.1.1 Anterior Inflammatory Disease: Under-diagnosed and Under-treated?
  11.1.2 On Current Developments in Ocular Inflammation and Therapeutic Agents
  11.1.3 On Future Treatments for Ophthalmic Inflammatory Disorders
  11.1.4 R&D and Pipeline Developments
  11.1.5 On Therapeutic Areas Offering Growth Opportunities
11.2 Dr Victor Chong, MD, FRCS, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Senior Lecturer in Ophthalmology, University of Oxford, Oxford Eye Hospital, Oxford, UK
  11.2.1 Key Unmet Needs
  11.2.2 Research and Development
  11.2.3 Limitations of Ophthalmic Treatments
  11.2.4 Challenges in the Development of Ophthalmic Drugs
  11.2.5 Complexities Involved in Developing New Ophthalmic Drugs
  11.2.6 Growth Opportunities in the Ophthalmic Drug Market
  11.2.7 Challenges Facing the Ophthalmic Pharmaceutical Industry
  11.2.8 Main Regions Offering Growth Potential
  11.2.9 Needs of Glaucoma Patients
  11.2.10 Future Treatments for Glaucoma
  11.2.11 Pipeline Developments from a Physician's Perspective
  11.2.12 Prospects for Replacing Current Treatments
  11.2.13 Novel Treatments for Ophthalmic Diseases
11.3 Dr Christopher Rhodes, PhD, Chief Technology Officer, SKS Ocular, San Diego, California, USA
  11.3.1 Key Unmet Needs
  11.3.2 Challenges Facing the Ophthalmic Pharmaceutical Industry
  11.3.3 Limitations of Ophthalmic Treatments
  11.3.4 On Ocular SKS and Ophthalmic Market
  11.3.5 On R&D and Ophthalmic Market in the Future
  11.3.6 On Therapeutic Areas Offering Growth Opportunity
11.4 Professor David T. Shima, PhD, Institute of Ophthalmology, University College London, UK
  11.4.1 On the Role of VEGF in Retinal Disorders
  11.4.2 On Candidate Molecule E10030
  11.4.3 On Candidate Molecule JSM 6427
  11.4.4 On New Sustained Release Formulations
  11.4.5 On Delta-Notch Signalling
  11.4.6 Potential Clinical Crossovers Between Ophthalmology and Oncology
  11.4.7 Commercial and Clinical Possibilities in the Ophthalmology Market
  11.4.8 On the Possibilities of Research into the Endothelial Fenestra
11.5 Dr Paul Ashton, President & CEO, pSivida, Watertown, MA, USA
  11.5.1 On the Challenge of Getting Drugs to the Retina
  11.5.2 On pSivida's Drug Delivery Platforms
  11.5.3 On Iluvien and DR/DME
  11.5.4 On Implant Technology and Drug Delivery
  11.5.5 On pSivida's Pipeline Products
  11.5.6 On Lucentis, Avastin and VEGF-Trap
  11.5.7 On Challenges of siRNA
11.6 Expert Interview 6: Authority from a Company in the Sector (Views Provided Anonymously)
  11.6.1 Key Unmet Needs
  11.6.2 Challenges facing Ophthalmic Sector
  11.6.3 On Current Ophthalmic Treatments and their Effectiveness
  11.6.4 On Opportunities in the Ophthalmic Sector
11.7 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor, MI, USA
  11.7.1 The Optogenetic Approach to Vision Restoration
  11.7.2 Choosing Disease Targets and Delivery Vectors
  11.7.3 The Regulatory Picture
  11.7.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas
  11.7.5 The Next Ten Years for Gene Therapy
11.8 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA
  11.8.1 MC-1101: Identifying and Treating Chiou Syndrome
  11.8.2 Preventing Dry AMD Progression
  11.8.3 Treating the Root Cause of Dry AMD
  11.8.4 Phase III: Endpoints and Prospects for MC-1101
11.9 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida, USA
  11.9.1 The Impact of Eylea, 2011-2012
  11.9.2 The Comparative Dosing Schedules of Eylea and Lucentis
  11.9.3 Patient Transitioning to Eylea: Salvage Switching
  11.9.4 Avastin after the CATT Study
  11.9.5 Prospects for Eylea in Other Indications and Combinations
  11.9.6 Future Possibilities in Wet AMD Treatment

12. CONCLUSIONS

12.1 Ophthalmic Pharmaceuticals: An Attractive Niche Market
12.2 Ophthalmic Pharmaceutical Market Forecast to 2023
12.3 What Will Succeed in the Ophthalmic Pharmaceutical Market?
12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest?

LIST OF FIGURES

Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2011
Figure 3.2 Top Ten Ophthalmic Pharmaceutical Manufacturers: Market Shares, 2011
Figure 3.3 World Ophthalmic Pharmaceutical Market: Revenue Forecast, 2011-2023
Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Shares and Revenue Forecasts, 2011-2023
Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Revenue Forecasts, 2011-2023
Figure 4.1 Leading Anti-Glaucoma Brands: Market Shares, 2011
Figure 4.2 World Anti-Glaucoma Market: Sales Forecast, 2011-2017
Figure 4.3 World Anti-Glaucoma Market: Sales Forecast, 2018-2023
Figure 4.4 Leading Anti-Glaucoma Brands: Market Shares, 2017
Figure 4.5 Xalabrands (Xalatan/Xalacom) Sales Forecast, 2011-2017
Figure 4.6 Xalabrands (Xalatan/Xalacom) Sales Forecast, 2018-2023
Figure 4.7 Lumigan Franchise Sales Forecast, 2011-2017
Figure 4.8 Lumigan Franchise Sales Forecast, 2018-2023
Figure 4.9 Cosopt/Trusopt Sales Forecast, 2011-2017
Figure 4.10 Cosopt/Trusopt Sales Forecast, 2018-2023
Figure 4.11 Travatan Z Sales Forecast, 2011-2017
Figure 4.12 Travatan Z Sales Forecast, 2018-2023
Figure 4.13 Alphagan Sales Forecast, 2011-2017
Figure 4.14 Alphagan Sales Forecast, 2018-2023
Figure 4.15 Combigan Sales Forecast, 2011-2017
Figure 4.16 Combigan Sales Forecast, 2018-2023
Figure 4.17 Azopt Sales Forecast, 2011-2017
Figure 4.18 Azopt Sales Forecast, 2018-2023
Figure 4.19 Extravan/DuoTrav Sales Forecast, 2011-2017
Figure 4.20 Extravan/DuoTrav Sales Forecast, 2018-2023
Figure 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2011
Figure 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands: Market Shares, 2011
Figure 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2011-2017
Figure 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2018-2023
Figure 5.5 Patanol Sales Forecast, 2011-2017
Figure 5.6 Patanol Sales Forecast, 2018-2023
Figure 5.7 Vigamox Sales Forecast, 2011-2017
Figure 5.8 Vigamox Sales Forecast, 2018-2023
Figure 5.9 TobraDex Sales Forecast, 2011-2017
Figure 5.10 TobraDex Sales Forecast, 2018-2023
Figure 5.11 Pataday Sales Forecast, 2011-2017
Figure 5.12 Pataday Sales Forecast, 2018-2023
Figure 5.13 Cravit Sales Forecast, 2011-2017
Figure 5.14 Cravit Sales Forecast, 2018-2023
Figure 5.15 Acular Sales Forecast, 2011-2017
Figure 5.16 Acular Sales Forecast, 2018-2023
Figure 5.17 Xibrom/Bromday Sales Forecast, 2011-2017
Figure 5.18 Xibrom/Bromday Sales Forecast, 2018-2023
Figure 6.1 Therapeutic Category Market Shares in the Retinal Disorder Market, 2011
Figure 6.2 Leading Retinal Disorder Brands: Market Shares, 2011
Figure 6.3 World Retinal Disorder Market: Sales Forecast, 2011-2017
Figure 6.4 World Retinal Disorder Market: Sales Forecast, 2018-2023
Figure 6.5 Lucentis: Sales Breakdown, 2008-2011
Figure 6.6 Lucentis Sales Forecast, 2011-2017
Figure 6.7 Lucentis Sales Forecast, 2018-2023
Figure 6.8 Eylea Sales Forecast, 2011-2017
Figure 6.9 Eylea Sales Forecast, 2018-2023
Figure 6.10 Visudyne Sales Forecast, 2011-2017
Figure 6.11 Visudyne Sales Forecast, 2018-2023
Figure 7.1 World Dry Eye Market: Sales Forecast, 2011-2017
Figure 7.2 World Dry Eye Market: Sales Forecast, 2018-2023
Figure 7.3 Restasis Sales Forecast, 2011-2017
Figure 7.4 Restasis Sales Forecast, 2018-2023
Figure 7.5 Refresh Brand, including Celluvisc Sales Forecast, 2011-2017
Figure 7.6 Refresh Brand, including Celluvisc Sales Forecast, 2018-2023
Figure 7.7 Hyalein Sales Forecast, 2011-2017
Figure 7.8 Hyalein Sales Forecast, 2018-2023
Figure 8.1 Global Population Aged Over 65, 2010-2025
Figure 8.2 Population Aged 65 Years or Over in Major Ophthalmic Pharmaceutical Country Markets, 2009 and 2025
Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030
Figure 9.1 Leading National Ophthalmic Drug Markets: Market Shares, 2011
Figure 9.2 Leading National Ophthalmic Drug Markets: Market Shares, 2017
Figure 9.3 Leading National Ophthalmic Drug Markets: Market Shares, 2020
Figure 9.4 Leading National Ophthalmic Drug Markets: Market Shares, 2023
Figure 9.5 US and Japanese Ophthalmic Drug Markets: Revenue Forecasts, 2011-2023
Figure 9.6 EU5, Brazilian, Indian and Chinese Ophthalmic Drug Markets: Revenue Forecasts, 2011-2023
Figure 12.1 Ophthalmic Pharmaceutical Market: World Revenues by Therapeutic Category, 2011, 2013, 2017, 2019, 2021 & 2023
Figure 12.2 Ophthalmic Pharmaceutical Market: Overall World Revenue, 2011, 2013, 2017, 2019, 2021 & 2023
Figure 12.3 Ophthalmic Pharmaceuticals: Leading National Revenue Forecasts, 2011, 2013, 2017, 2019, 2021 & 2023

COMPANIES LISTED

Acucela
Alcon (Novartis)
Alexion
Alimera Sciences
Allegro Ophthalmics
Allergan
American Academy of Ophthalmology (AAO) [US]
American Society of Retina Specialists (ASRS) [US]
Apotex
Asahi Glass
AstraZeneca
Avalanche Biotechnologies
Bausch & Lomb
Bayer
Biogen Idec
Biovitrum
Bristol-Myers Squibb
Can-Fite BioPharma
Cerimon Pharmaceuticals
Chugai Pharmaceutical Corp.
CombinatoRx
CoMentis
Control Delivery Systems
Daiichi Sankyo
Danube Pharmaceuticals
Eli Lilly and Company
Esteve
European Medicines Agency (EMEA/EMA)
EyeGate Pharmaceuticals
Food and Drug Administration (FDA) [US]
ForSight VISION4
Fovea Pharmaceuticals
Galderma International SA (Nestlй and L'Orйal)
Genentech
Genzyme
GlaxoSmithKline
Gruenenthal
Icon Bioscience
InSite Vision
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Johnson & Johnson
Kaplan Medical Center
Kowa Company
KYORIN Pharmaceutical Corp.
Kyowa Hakko Kirin Corp.
Laboratorios Sophia
LEO Pharma
Lions Eye Institute of Perth
Lpath
Lux Biosciences
MacuCLEAR
Mayo Clinic College of Medicine [US]
Meda Pharmaceuticals
Merck & Co.
MerLion Pharmaceuticals
Ministry of Health, Labour and Welfare [Japan]
Moorfields Eye Hospital [UK]
Mylan
Mystic Pharmaceuticals
National Eye Institute (NEI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Neurotech
NicOx
NovaBay Pharmaceuticals
Novagali Pharma
Novartis
Oakwood Laboratories
OcuSciences
OHR Pharmaceutical
Ophthotech
OPKO Health
OSI Pharmaceuticals
Цsterreichische Agentur fьr Gesundheit und Ernдhrungssicherheit (AGES, Austrian Agency for Health and Food Safety)
Othera Pharmaceuticals
Otsuka Pharmaceutical Corp.
Oxford BioMedica
Oxford Eye Hospital [UK]
OXiGENE
Paladin Labs
PDL BioPharma
PanOptica
Pfizer
pSivida Corp.
QLT
Quark Pharmaceuticals
Ranbaxy Laboratories
Regeneron Pharmaceuticals
RetroSense Therapeutics
ReVision Therapeutics
Roche
Rutgers University, Springfield, New Jersey [US]
Santen Pharmaceutical Corp.
Sanwa Kagaku Kenkyusho Corp.
SARcode Corporation
Senju Pharmaceuticals
Shire
Silence Therapeutics
Sirion Therapeutics
Sirna Therapeutics
SKS Ocular
STARx Allergy and Asthma Centre
Sunesis Pharmaceuticals
Symphony ViDA
Takeda Pharmaceuticals Corp.
Targeted Genetics Corp.
Teva
ThromboGenics
University College of London (UCL), Institute of Ophthalmology [UK]
University of Aston, Birmingham [UK]
University of Michigan [US]
University of Oxford [UK]

Lucentis Controls the Retinal Disorder Market in 2011 

Sales of Lucentis (ranibizumab, Genentech/Roche/Novartis), indicated for the treatment of patients with wet AMD, were $3772m in 2011 and $2935m in 2010 compared to $2338m for the fiscal year 2009 (Table 6.2 and Figure 6.2). In 2007 rapid domination of the wet AMD market occurred, when Lucentis revenues grew to $1208m, and increased further to $1761m in 2008.Lucentis is an antibody fragment (recombinant humanised IgG1 kappa isotype monoclonal antibody fragment), which binds to and inhibits the biologic activity of vascular endothelial growth factor A (VEGF-A), a growth factor essential for the formation of new blood vessels. By binding to VEGF-A, Lucentis reduces abnormal vessel growth and leakage of fluid into the retina. This allows the retinal structure to return to normal. Lucentis is the first such treatment that has been shown to improve vision rather than simply slow vision loss. Lucentis stabilises vision in most wet AMD patients treated, and improves vision and vision-related quality of life in a significant number of patients, reports indicate. Lucentis is recommended to be administered by intravitreous injection once a month.

Genentech/Roche markets Lucentis in the US, where the FDA approved the drug in June 2006. Lucentis was Roche's number ten best selling pharmaceutical product in 2008. It maintained that position in 2009, generating sales revenues of $1121m for the company. Roche reported annual revenues for the drug of 1,523CHF ($1402m) for 2010 and $1722m in 2011. Novartis markets Lucentis outside the US, and achieved $1217m in sales in 2009. Novartis reported sales of $1533m and $2050m for the 12 month period to Q4 in 2010 and 2011 respectively. Lucentis was approved for use in the EU in January 2007 and is now marketed in many markets worldwide, including Japan since April 2009.

Visudyne was the Second Highest Selling Retinal Disorder Drug in 2011

Visudyne (verteporfin, QLT/Novartis) is indicated for the treatment of patients with the predominantly classic variant of AMD (comprising about a quarter of AMD patients). Therapy involves intravenous infusion of Visudyne, followed by exposure of the eye to a non-thermal diode laser. This activates the drug and produces a reaction that destroys abnormal blood vessels. Visudyne therapy is typically given approximately every three months and as many times as needed, to prevent re-growth of abnormal blood vessels (typically six to seven treatments over two to three years). Visudyne does not restore vision, however. The FDA approved Visudyne in 2000, and it is now marketed worldwide. Visudyne was the second-highest selling retinal disorder drug of 2009, with total revenues of $106m. Sales in 2010 declined to $91m, a decline of 14.5% over the previous year. In 2011 sales remained steady to record $90m.

The material was prepared in July, 2013.

LIST OF TABLES

Table 2.1 Glaucoma Drug Types, 2013
Table 2.2 AMD Drug Types, 2013
Table 2.3 Ophthalmic Allergy Drug Types, 2013
Table 2.4 Ophthalmic Inflammatory Disorder Drug Types, 2013
Table 2.5 Ophthalmic Anti-Infective Drug Types, 2013
Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Sales and Market Shares, 2011
Table 3.2 Top 20 Ophthalmic Pharmaceutical Brands: Sales and Market Shares, 2011
Table 3.3 Top 10 Ophthalmic Pharmaceutical Manufacturers: Sales and Market Shares, 2011
Table 3.4 World Ophthalmic Pharmaceutical Market: Revenue Forecast, 2011-2017
Table 3.5 World Ophthalmic Pharmaceutical Market: Revenue Forecast, 2018-2023
Table 3.6 World Ophthalmic Pharmaceutical Market by Therapeutic Category: Revenue Forecasts, 2011-2017
Table 3.7 World Ophthalmic Pharmaceutical Market by Therapeutic Category: Revenue Forecasts, 2018-2023
Table 4.1 Leading Anti-Glaucoma Brands: Sales and Market Shares, 2011
Table 4.2 World Anti-Glaucoma Market: Sales Forecast, 2011-2017
Table 4.3 World Anti-Glaucoma Market: Sales Forecast, 2018-2023
Table 4.4 Leading Anti-Glaucoma Brands: Sales Forecasts, 2011-2017
Table 4.5 Leading Anti-Glaucoma Brands: Sales Forecasts, 2018-2023
Table 5.1 Therapeutic Category Sales and Market Shares in the Ophthalmic Anti-Allergy/ Inflammatory/Infective Segment, 2011
Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales and Market Shares, 2011
Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2011-2017
Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2018-2023
Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales Forecasts, 2011-2017
Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales Forecasts, 2018-2023
Table 6.1 Therapeutic Category Sales and Market Shares in the Retinal Disorders Segment, 2011
Table 6.2 Leading Retinal Disorder Brands: Sales and Market Shares, 2011
Table 6.3 World Retinal Disorder Market: Sales Forecast, 2011-2017
Table 6.4 World Retinal Disorder Market: Sales Forecast, 2018-2023
Table 6.5 Leading Retinal Disorder Brands: Sales Forecasts, 2011-2017
Table 6.6 Leading Retinal Disorder Brands: Sales Forecasts, 2018-2023
Table 7.1 Leading Dry Eye Brands: Sales and Market Shares, 2011
Table 7.2 World Dry Eye Market: Sales Forecast, 2011-2017
Table 7.3 World Dry Eye Market: Sales Forecast, 2018-2023
Table 7.4 Leading Dry Eye Brands: Sales Forecasts, 2011-2017
Table 7.5 Leading Dry Eye Brands: Sales Forecasts, 2018-2023
Table 8.1 SWOT Analysis: Strengths and Weaknesses of the World Ophthalmic Drugs Market, 2013-2023
Table 8.2 SWOT Analysis: Opportunities and Threats in the World Ophthalmic Drugs Market, 2013-2023
Table 8.3 Expected Patent Expiries for Leading Ophthalmic Pharmaceuticals, 2009-2014
Table 8.4 Ophthalmic Disorder Prevalence Forecasts
Table 9.1 Leading National Markets for Ophthalmic Pharmaceuticals: Sales and Market Shares, 2011
Table 9.2 Leading National Markets for Ophthalmic Drugs: Revenue Forecasts, 2011-2017
Table 9.3 Leading National Markets for Ophthalmic Drugs: Revenue Forecasts, 2018-2023
Table 10.1 Select Drugs in the Anti-Glaucoma Pipeline, 2013
Table 10.2 Select Drugs in the Ophthalmic Anti-Allergy Pipeline, 2013
Table 10.3 Select Drugs in the Ophthalmic Anti-Inflammatory Pipeline, 2013
Table 10.4 Select Drugs in the Ophthalmic Anti-Infective Pipeline, 2013
Table 10.5 Select Drugs in the Retinal Disease Pipeline, 2013
Table 10.6 Select Drugs in the Dry Eye Pipeline, 2013
Table 10.7 Select R&D Pipeline Drugs for Other Ophthalmic Indications, 2013

Skip to top


Ask Your Question

Ophthalmic Drugs: World Market Prospects 2013-2023
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: